Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529243 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects
A Phase 3 study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT00529243 is a Phase 3 study that has completed, run by Kaiser Permanente. The registered enrollment target is 52 participants.
The verdict
NCT00529243, a Phase 3 study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
The primary objective of this study is: To assess the virologic effect of changing enfuvirtide to MK-0518(raltegravir) in human immunodeficiency virus type 1(HIV-1) infected patients who have an undetectable level of serum human immunodeficiency virus(HIV) (\< 75 copies/ml by branch deoxyribonucleic acid (bDNA) assay, \< 50 copies/ml by Ultrasensitive Polymerase Chain Reaction(PCR) assay) on their current HIV medication regimen. Hypothesis: HIV-1 infected individuals well controlled on an enfuvirtide containing regimen with HIV RNA levels below limits of quantification can safely have the investigational integrase inhibitor, MK-0518 substituted for enfuvirtide without loss of virologic suppression.
Interventions
- DRUG raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529243
The ClinicalTrials.gov registry entry for NCT00529243 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which raltegravir is the first listed.
NCT00529243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529243 about?
NCT00529243 is a clinical study titled "Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects". The primary objective of this study is: To assess the virologic effect of changing enfuvirtide to MK-0518(raltegravir) in human immunodeficiency virus type 1(HIV-1) infected patients who have an undetectable level of serum human immunodeficiency virus(HIV) (\< 75 copies/ml by branch deoxyribonuclei...
What is the current status of trial NCT00529243?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2007-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00529243?
The interventions under investigation include: raltegravir (DRUG).
Who is sponsoring clinical trial NCT00529243?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.